Fierce Healthcare

JUNE 3, 2024

The nation’s largest nurses union is demanding that artificial intelligence tools used in healthcare be proven safe and equitable before deployment. | A union organization for nurses nationwide says the deployment of AI in healthcare will push nurses out of patient rooms and compromise patient safety. A new AI Bill of Rights lays out nurse and patient protections, which are not currently being met.

137

137

Pharmacy Times

JUNE 3, 2024

Promises of sexual improvement may ensnare unsuspecting patients with potentially dangerous adverse effects from untested OTC remedies.

137

137

pharmaphorum

JUNE 3, 2024

Understanding the challenges and opportunities in transitioning to IVDR for pharmacogenomics can be complex. Learn more about how to overcome these challenges effectively.

126

126

Pharmacy Times

JUNE 3, 2024

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Controlled Substances 132

Controlled Substances Hospitals 132

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Fierce Healthcare

JUNE 3, 2024

Blue Cross and Blue Shield of Kansas City is leaving the Medicare Advantage (MA) market at the end of 2024, the insurer announced recently. | Blue Cross and Blue Shield of Kansas City is opting out of the Medicare Advantage market. The health plan said its relatively low membership and burdensome regulatory factors meant the company no longer view the market as financially viable.

Insurance 123

Insurance 123

Pharmacy Times

JUNE 3, 2024

Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.

Hospitals 131

Hospitals 131

Pharmacy Times

JUNE 3, 2024

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

126

126

STAT

JUNE 3, 2024

It’s been one year since the U.S. surgeon general issued a national warning about an epidemic of loneliness. Other countries recognized the problem earlier: the United Kingdom appointed a minister for loneliness in 2018; Japan did the same in 2021. These initiatives have brought attention to — and spurred action around — an important problem with serious health consequences, which include increased risks of heart disease, dementia, and premature death.

119

119

Pharmacy Times

JUNE 3, 2024

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.

123

123

STAT

JUNE 3, 2024

In the rural California town where physician Atashi Mandal sees patients, Medicare Advantage is popular among the older residents, many of whom have multiple chronic health conditions. Problem is, there aren’t any in-network providers for several hundred miles. “My patients seem to be unaware of this major deficiency regarding participation in Medicare Advantage plans,” Mandal wrote in a recent letter to the Centers for Medicare and Medicaid Services.

Patient Care 119

Patient Care Hospitals Insurance 119

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 3, 2024

GSK planning to refile anti-BCMA drug Blenrep in the US for multiple myeloma after reporting positive results from the DREAMM-8 trial at ASCO

118

118

STAT

JUNE 3, 2024

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled. Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Prescription Filling 118

Prescription Filling Insurance 118

pharmaphorum

JUNE 3, 2024

AstraZeneca's ASCO 'super sunday' delivers new data for Tagrisso and Imfinzi in lung cancer and Enhertu in breast cancer

115

115

Fierce Pharma

JUNE 3, 2024

Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. | Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too.

113

113

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JUNE 3, 2024

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

113

113

pharmaphorum

JUNE 3, 2024

Join us for live coverage of BIO 2024, featuring Viola Davis and Brooke Baldwin on Day 1. Stay tuned for exclusive updates and highlights from the event.

113

113

Drug Topics

JUNE 3, 2024

Research presented at ENDO 2024 found that environmental stress increased the likelihood of earlier alcohol, nicotine and cannabis use in females and traumatic events increased the likelihood in males.

112

112

Fierce Pharma

JUNE 3, 2024

Thanks to a shortage of the isotope actinium, RayzeBio has temporarily halted new patient enrollment in its phase 3 study in neuroendocrine tumors.

111

111

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

JUNE 3, 2024

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith , is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

110

110

Fierce Pharma

JUNE 3, 2024

In the field of anti-CD38 treatment for multiple myeloma, Johnson & Johnson’s Darzalex casts a long shadow. Now, Sanofi hopes a first-in-class win will help its Sarclisa gain an edge. | In the field of anti-CD38 treatment for multiple myeloma, Johnson & Johnson’s Darzalex casts a long shadow. Now, Sanofi hopes a first-in-class win will help its Sarclisa gain an edge.

108

108

pharmaphorum

JUNE 3, 2024

Shares in GSK plummet after Delaware court says litigation claiming Zantac can cause cancer is cleared to go ahead

108

108

STAT

JUNE 3, 2024

In today’s labor market, good help is hard to find. For companies developing antibiotics, it’s becoming nearly impossible. Three years ago, I became CEO of the AMR Action Fund , which is investing approximately $1 billion in biotech companies developing treatments for antimicrobial-resistant infections, a growing global health crisis that now contributes to 4.9 million deaths every year.

106

106

pharmaphorum

JUNE 3, 2024

The BIOSECURE Act is a proposed legislation that reflects the current strained US-Chinese relations, impacting biotech cooperation. Learn more about the implications and challenges.

108

108

Pharmacy Times

JUNE 3, 2024

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).

105

105

Pharmaceutical Commerce

JUNE 3, 2024

The latest news for pharma industry insiders.

105

105

The Checkup by Singlecare

JUNE 3, 2024

Hydrochlorothiazide is a prescription medication used to treat high blood pressure, also known as hypertension. “Hydrochlorothiazide, or HCTZ, belongs to a class of diuretics (water pills) known as thiazide diuretics ,” says Ken Zweig, MD , an internist practicing in Arlington, Virginia. It’s also used to treat edema, which is swelling caused by the build-up of fluid in the body’s tissues.

Labelling 103

Labelling FDA 103

Fierce Pharma

JUNE 3, 2024

As Japanese chemical giant Asahi Kasei continues its foray into the biopharma contract manufacturing space, the company’s biologics CDMO is expanding its offerings to include starting materials for | Asahi’s U.S. subsidiary Bionova Scientific is launching a new business line to provide services around plasmid DNA (pDNA), the companies announced Monday.

102

102

STAT

JUNE 3, 2024

More than a year ago, Kaiser Permanente made waves when it said it was creating a new, sprawling entity of nonprofit hospitals and doctors with Geisinger as its first takeover — the latest example of health care companies bulking up in an already highly consolidated industry. Nothing has happened since then, at least publicly. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health.

Hospitals 102

Hospitals Health Insurance Companies Insurance 102

Fierce Pharma

JUNE 3, 2024

The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left four major drugmakers—GSK, Pfizer, Sanofi and Boehringer Ingelheim—vulnera | The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left four major drugmakers—GSK, Pfizer, Sanofi and Boehringer Ingelheim—vulnerable to costly awards, settlements and litigation fees as they try to resolve claims that the heartburn

101

101

Pharmacy Times

JUNE 3, 2024

Providers, the community, health systems, and health policies can all play a part in addressing various challenges in care for obesity.

101

101

Drug Topics

JUNE 3, 2024

All Boehringer Ingelheim inhalers are included in the program and will be available for $35 per month for eligible patients.

98

98

Pharmaceutical Technology

JUNE 3, 2024

Moderna has secured approval from the US Food and Drug Administration (FDA) for mRESVIA (respiratory syncytial virus vaccine).

Vaccines 98

Vaccines FDA 98

Drug Topics

JUNE 3, 2024

Check out this recap of articles published on our sister sites during the past week.

98

98